Navigation Links
Perrigo to Introduce New Dosing System and Labeling for Certain Pediatric Pain Relievers

ALLEGAN, Mich., May 5, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced it will be changing the dosing device for pediatric suspensions from a dropper to a new syringe dosing system designed to help consumers more clearly dispense the proper amount of medication. The company will also be labeling its dye-free infants' and children's pediatric suspensions as high-fructose corn syrup-free.

(Photo: )

These product improvements will occur this summer when Perrigo and other manufacturers transition to the same single concentration (160 mg / 5 mL) for all single-ingredient over-the-counter (OTC) pediatric liquid acetaminophen products.  At that time, Perrigo's new infant acetaminophen formulas will contain the same amount of active ingredient (per mL) as the current children's pain relief formulas on the market.  Based on a January 2011 survey of 400 practicing pediatricians, Perrigo found that pediatricians support this improvement. Over 80 percent of pediatricians surveyed thought that the active ingredient concentration (per mL) of infant and children's acetaminophen OTC liquid pain reliever/fever reducers should be the same.

A majority of the pediatricians also support the move from a dropper to a syringe dosing system, primarily because they felt the syringe was more accurate, safe and hygienic.  Perrigo will be conducting an extensive pediatrician outreach program to educate pediatricians on the new changes.

Perrigo also recently conducted extensive research with parents on infants' and children's OTC products that relieve pain and reduce fever.  More than half of the 600 mothers surveyed indicated a preference for children's medications that contained no high-fructose corn syrup.  In response, Perrigo will begin labeling their dye-free formulas as "high-fructose corn syrup free."  As part of an earlier, industry-first initiative, all of Perrigo's infant pediatric acetaminophen products will be available with "gluten free" labeling.

"At Perrigo, we pride ourselves in bringing meaningful improvements to market, while continuing to deliver the highest quality and the best value to consumers," said Perrigo's chairman and CEO Joseph C. Papa.

Perrigo is the world's largest manufacturer of over-the-counter (OTC) pharmaceutical products for the store brand market. Today, more than 95 percent of "store brand" – meaning those found under retailers' own brand labels – pediatric acetaminophen and ibuprofen suspensions are manufactured for retailers by Perrigo. The company's infants', children's and adult's ibuprofen and acetaminophen-based pain relievers are manufactured under the same FDA guidelines and contain the same FDA-approved active ingredients as the national brand.  They are available in leading pharmacies and retailers.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance
2. Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Mens Rogaine® Foam
3. Perrigo Company Announces Quarterly Dividend
4. Perrigos PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
5. Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets
6. Perrigo Announces Conclusion of the FDA Re-Inspection
7. Perrigo Company to Present at the Barclays Capital 2011 Global Health Care Conference
8. Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter
9. Perrigo Company to Present at the Citi 2011 Global Health Care Conference
10. Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma
11. Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix for Store Brand Blood Glucose Monitoring Products
Post Your Comments:
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... -- --> --> Juntendo ... optimal contrast weighting of MRI for patients with Multiple ... research agreement with SyntheticMR in order to use SyMRI in ... possible to generate multiple contrast images from a single scan ... thus making it possible to both fine tune images and ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... Narconon network, announced the release of a new cutting edge recovery program that has ... been working with drug- and alcohol-addicted individuals with the purpose to free addicts from ...
(Date:11/25/2015)... ... , ... Smiles by Stevens is pleased to announce the addition ... many patients are aware of the benefits of Botox® in the treatment of moderate ... with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
Breaking Medicine News(10 mins):